We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

102 hedge funds and large institutions have $863M invested in Portola Pharmaceuticals, Inc. in 2014 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 43 increasing their positions, 19 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 19

86% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 14

50% more funds holding in top 10

Funds holding in top 10: 46 (+2)

11% more funds holding

Funds holding: 92102 (+10)

9% more capital invested

Capital invested by funds: $792M → $863M (+$70.8M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $31K

Holders
102
Holders Change
+10
Holders Change %
+10.87%
% of All Funds
2.94%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.17%
New
26
Increased
43
Reduced
19
Closed
14
Calls
Puts
$31K
Net Calls
-$31K
Net Calls Change
-$31K
Name Holding Trade Value Shares
Change
Change in
Stake
Wells Fargo
26
Wells Fargo
California
$5.91M +$945K +35,394 +18%
Millennium Management
27
Millennium Management
New York
$5.35M +$4.96M +185,847 +896%
PI
28
Putnam Investments
Massachusetts
$5.19M +$10.7K +400 +0.2%
BCM
29
BBT Capital Management
Texas
$5.18M -$943K -35,335 -15%
CAM
30
Cormorant Asset Management
Massachusetts
$5.18M +$3.34M +125,000 +167%
EMFAT
31
Emerald Mutual Fund Advisers Trust
Pennsylvania
$5.12M -$3.28M -123,010 -38%
Adage Capital Partners
32
Adage Capital Partners
Massachusetts
$4.73M
BBA
33
Baker Bros. Advisors
New York
$4.73M -$1.12M -41,843 -19%
Northern Trust
34
Northern Trust
Illinois
$4.58M +$868K +32,526 +23%
State Street
35
State Street
Massachusetts
$4.17M -$19.4K -727 -0.4%
Morgan Stanley
36
Morgan Stanley
New York
$3.61M +$1.62M +60,777 +77%
FIM
37
Fernwood Investment Management
Massachusetts
$3.07M -$2.73M -102,201 -46%
MAA
38
Managed Account Advisors
New Jersey
$2.78M +$2.29M +85,810 +400%
HCM
39
Harvey Capital Management
Florida
$2.77M +$1.7M +63,530 +146%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$2.66M +$94.4K +3,538 +4%
BA
41
BlackRock Advisors
Delaware
$2.61M +$749K +28,049 +39%
MSA
42
Mason Street Advisors
Wisconsin
$2.45M +$699K +26,180 +38%
Norges Bank
43
Norges Bank
Norway
$2.39M
RSCM
44
Rail-Splitter Capital Management
Illinois
$2.35M +$2.42M +90,680 New
TCIM
45
TIAA CREF Investment Management
New York
$2.2M +$271K +10,169 +14%
PAMU
46
Pictet Asset Management (UK)
United Kingdom
$1.63M +$286K +10,700 +21%
Geode Capital Management
47
Geode Capital Management
Massachusetts
$1.56M +$344K +12,884 +27%
Macquarie Group
48
Macquarie Group
Australia
$1.51M +$126K +4,735 +9%
TC
49
TFS Capital
Pennsylvania
$1.08M +$190K +7,117 +21%
ProShare Advisors
50
ProShare Advisors
Maryland
$1.07M +$620K +23,224 +127%

PTLA Hedge Fund Activity: Q1 2014 in Review

102 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q1 2014, worth a combined $863M — up 8.9% from $792M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new PTLA positions and 14 closed out — a net gain of 12 holders — while 43 added to existing stakes and 19 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $43.4M. The largest seller was MPM Asset Management, cutting an estimated $32.6M.

  • 102 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q1 2014, up from 92 in Q4 2013.
  • Funds reported $863M of Portola Pharmaceuticals, Inc. stock for Q1 2014, up 8.9% quarter-over-quarter.
  • 26 funds opened new Portola Pharmaceuticals, Inc. positions in Q1 2014 and 14 closed out, a net change of +12 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q1 2014 was Fidelity Investments, an estimated $43.4M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q1 2014 was MPM Asset Management, an estimated $32.6M sold.

Based on aggregated 13F filings for Q1 2014.